Clinical trials: RNA
Infections, Coronavirus
Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19
The study is designed as an open observational non-comparative study of Polyoxidonium®, lyophilizate for solution for injections and topical application, 12 mg in hospitalized patients with coronavirus disease (COVID-19).
- Trial name
- NCT04542226
- Testing
- Polyoxidonium
- Where
- 5 sites in Belarus, Russia
- Volunteers
- 81 people
- Sponsor
- NPO Petrovax
COVID-19, Lymphocytopenia
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients
- Trial name
- ILIAD-7-US-I (NCT04442178)
- Testing
- CYT107
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Revimmune
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Genotype 1
Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus
The purpose of this open label study is to evaluate the safety and efficacy of daclatasvir plus pegylated interferon-alfa 2a and ribavirin in untreated hepatitis C virus in patients coinfected with HIV
- Trial name
- NCT01471574
- Testing
- Daclatasvir, Ribavirin, PEG-Interferon alfa 2a
- Where
- 86 sites in United States, Argentina and 11 more
- Volunteers
- 549 people
- Sponsor
- Bristol-Myers Squibb
Influenza
Yearly Licence Tolerability and Immunogenicity Study of Fluval AB Seasonal Influenza Vaccine to be Used in the 2012/2013 Vaccination Season
This is a yearly licence tolerability and immunogenicity study of Fluval AB suspension for injection (trivalent, seasonal influenza vaccine, active ingredient content: 15 μgHA/strain/0.5mL) in adult and elderly subjects to assess…
- Trial name
- NCT01649713
- Testing
- Fluval AB vaccination
- Where
- 3 sites in Hungary
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
HIV Infections
A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers
The objective of this double-blind placebo-controlled study is to evaluate the effect of Isoprinosine in a group of homogenous male volunteers who present with immunologic defects relative to: Comparison of total helper and…
- Trial name
- NCT00002059
- Testing
- Inosine pranobex
- Where
- United States
- Sponsor
- Newport Pharmaceuticals International
Influenza
Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)
The objective of this study is to assess the safety, tolerability and immunogenicity of a Split Virus, Vero Cell derived, Seasonal Influenza Vaccine (VCIV) in comparison to a Licensed Egg Derived, Split Virus, Seasonal Influenza…
- Trial name
- NCT00424086
- Testing
- Inactivated seasonal influenza vaccine (split virus, vero cell derived), Inactivated seasonal influenza vaccine (split virus, egg derived) [licensed control vaccine]
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Covid19
Clinical Performance Evaluation of KnowNow SARS-CoV-2 Test for the Detection of COVID-19 Antigen
This is an international, multicentre, non-interventional, observational study to assess the clinical diagnostic performance of a rapid, point of care (POC) COVID-19 (SARS-CoV-2) antigen In vitro diagnostic (IVD), The KnowNow…
- Trial name
- NCT04733170
- Testing
- KnowNow SARS-CoV-2 Rapid Antigen Test
- Volunteers
- 600 people
- Sponsor
- Vatic Ltd.
Cytomegalovirus Infections, HIV Infections
Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections
To provide ganciclovir on a compassionate use basis to immunocompromised patients with serious cytomegalovirus (CMV) infections and to study safety and efficacy in this patient population.
- Trial name
- NCT00002024
- Testing
- Ganciclovir
- Where
- United States
- Sponsor
- Hoffmann-La Roche
Diphtheria, Tetanus
Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age
This is a phase II, randomized, double-blind, active-controlled, parallel-group, multicenter study to evaluate the immunogenicity and safety of DTaP-HepB-IPV-Hib hexavalent vaccine LR20062 in healthy infants as primary series at…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT06618196
- Testing
- LR20062, DTaP-HepB-IPV-Hib vaccine
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- LG Chem
HCV Infection
Study to Evaluate the Performance of the INSTI® HCV Antibody Test for Point-of-Care Use in Individuals at Risk for HCV Infection or Presenting With Signs or Symptoms of HCV Infection
A multicenter prospective study to evaluate the clinical performance, usability, and contrived result interpretation of the INSTI® HCV Antibody Test (INSTI HCV) with fingerstick (FS) whole blood specimens from participants with…
- Trial name
- NCT07904403
- Testing
- INSTI HCV Antibody Test
- Volunteers
- 1,660 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
COVID-19
Single-Blind Study of STAT-205 in Mild COVID-19
This is a randomized, single blind, study. Males and females meeting inclusion criteria who have symptoms of mild COVID-19 and in whom a positive PCR result for SARS-CoV-2 is obtained may be enrolled to the study treatment within…
- Trial name
- NCT04708327
- Testing
- STAT-205
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cytocom, Inc.
Poliomyelitis
Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell)
The study aimed to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio vaccine in infants aged two months (60~89 days).
- Trial name
- NCT07297186
- Testing
- sIPV, wIPV
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Diabetic Kidney Disease (DKD)
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease.
- Trial name
- ANCHOR-POC (NCT07271186)
- Testing
- ALN-ANG3, Evinacumab
- Where
- 59 sites in United States
- Volunteers
- 195 people
- Sponsor
- Regeneron Pharmaceuticals
COVID-19
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
- Trial name
- NCT04486313
- Testing
- Nitazoxanide, Vitamin Super B-Complex
- Where
- 2 sites in United States
- Volunteers
- 935 people
- Sponsor
- Romark Laboratories L.C.
Respiratory Syncytial Virus Infections
Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants
The purpose of this study was to evaluate the safety and immune response to a single intramuscular (IM) dose of GSK Biologicals' investigational RSV maternal vaccine (RSVPreF3) in healthy pregnant women 18-40 years of age and in…
- Trial name
- NCT04126213
- Testing
- RSV MAT 60 µg, RSV MAT 120 µg
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 534 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants
This open-label, single dose study in approximately 5 healthy male and female (of non childbearing potential only) participants has been designed to characterize mass balance and further the understanding of human…
- Trial name
- NCT05050682
- Testing
- PF-07304814
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS-CoV 2 Infection, Covid19
Qualitative Evaluation of Tear Fluid and Blood for Auto Antibodies Produced in Response to COVID-19
This study objective is to collect tear and blood samples from individuals with positive SARS-COV2 diagnosis and test those samples for the presence of various SARS-COV2 viral antigens and autoantibodies.
- Trial name
- NCT04542980
- Testing
- SARS-CoV2 Autoantibody detection
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Namida Lab
Encephalitis, Japanese Encephalitis
Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers
This is a long-term follow-up of the persistence of immune response in participants who previously received a single dose of JE-CV at age 12 to 18 months in Study JEC02 (NCT00735644) .
- Trial name
- NCT01001988
- Testing
- Blood sample, JE-CV administered in Study JEC02
- Where
- 4 sites in Philippines, Thailand
- Volunteers
- 596 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
HIV Infections
A Study of Two Anti-HIV Drug Combinations
The purpose of this study is to compare the safety and effectiveness of taking lamivudine (3TC) plus zidovudine (ZDV) plus a protease inhibitor (PI) with taking the 3TC/ZDV combination tablet (Combivir) plus a PI.
- Trial name
- NCT00002203
- Testing
- Lamivudine/Zidovudine, Lamivudine, Zidovudine
- Where
- 7 sites in United States, Puerto Rico
- Sponsor
- Glaxo Wellcome